Navigation Links
Nektar Therapeutics Reports Fourth Quarter and Year-End 2011 Financial Results
Date:2/29/2012

SAN FRANCISCO, Feb. 29, 2012 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the fourth quarter and year ended December 31, 2011.

Cash, cash equivalents, and investments at December 31, 2011 were $414.9 million as compared to $315.9 million at December 31, 2010. The 2011 year-end cash balance does not include the $124.0 million payment related to the sale of Cimzia and Mircera royalties also announced today.

"In 2011, Nektar continued to demonstrate that our technology platform is capable of generating multiple new drug candidates in high value therapeutic areas such as pain, oncology and hemophilia," said Howard W. Robin, President and Chief Executive Officer of Nektar. "In Q4, we achieved excellent results in our Phase 1 program for our new opioid molecule, NKTR-181 for chronic pain, and we are advancing it into Phase 2 this year.  We also began enrollment in our Phase 3 BEACON study for NKTR-102 in metastatic breast cancer.  Finally, BAX 855, a long-acting PEGylated Factor VIII therapy for hemophilia A, entered Phase 1 clinical development with our partner, Baxter."  

The company also announced today that AstraZeneca is planning regulatory filings in the US and EU in the middle of 2013 for NKTR-118 (naloxegol) in opioid-induced constipation. Naloxegol is currently in Phase 3 clinical development as a once-daily, oral tablet for the treatment of opioid-induced constipation.

Revenue for the fourth quarter of 2011 was $15.8 million. Revenue in the fourth quarter of 2011 decreased as compared to $45.3 million in the fourth quarter of 2010 primarily as a result of the completion as of December 31, 2010 of the amortization of the $125.0 million upfront payment received in 2009 from AstraZeneca for the NKTR-118 and NKTR-119 license agreement.

Total operating costs and expenses in the fourth qu
'/>"/>

SOURCE Nektar Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Nektar Commences Phase 2 Clinical Development Program for NKTR-102 (PEG-Irinotecan) in Colorectal Cancer
2. Nektar Commences Phase 2 Trial of NKTR-118 (oral PEG-naloxol) Evaluating Efficacy and Safety as Treatment for Opioid-Induced Bowel Dysfunction
3. Nektar Terminates All Negotiations With Potential Partners for Inhaled Insulin; Increased Number of Lung Cancer Cases Observed in Ongoing Clinical Studies of Inhaled Insulin Patients
4. Nektar Therapeutics to Present Positive Data at Upcoming Medical and Scientific Meetings
5. Nektar to Webcast Presentation of Phase 1 Clinical Results for Lead Small Molecule PEG-Oncolytic Program, NKTR-102 (PEG-irinotecan)
6. Nektar Announces Expanded Phase 2 Clinical Development Plan For NKTR-102 (PEG-irinotecan)
7. Nektar Announces Positive Results from Phase 2 Study of Oral NKTR-118 in Patients with Opioid-Induced Constipation (OIC)
8. Nektar Therapeutics Reports Second Quarter 2009 Financial Results
9. Nektar Presents Data Demonstrating Favorable Oral Bioavailability and Drug-Drug Interaction Profile for NKTR-118
10. Nektar Therapeutics Promotes Lorianne Masuoka, M.D. to Senior Vice President and Chief Medical Officer
11. Nektar Presents New Preclinical Data on NKTR-181 at Anesthesiology 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
(Date:9/1/2014)... (PRWEB) September 01, 2014 The B-cell ... growth across six major markets (the US, France, Italy, ... 2013 to $5.41 billion by 2018. , The competitive ... France, Italy, Germany, Spain and the UK is poised ... Disease management of the four largest B-cell NHL indications, ...
(Date:9/1/2014)... September 2014: Permanent atrial fibrillation (AF) doubles the risk ... in more than 6 000 patients presented at ESC ... findings suggest that a simple clinical assessment of the ... stroke risk. , Ischaemic stroke is the second cause ... million deaths and many more disabled patients each year. ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... can lay siege on the victim's disposition and way of ... of coolness can act as an effective pain// reliever. Scientists ... that enable feelings of coolness, and bring immense relief to ... for improved treatment measures for people suffering long-term pain, as ...
... President of the Canadian Medical Association (CMA) said that Canadian ... health of their own children// although in general they rated ... to a survey carried out by Ipsos-Reid, commissioned by the ... kids aged 2-17 are obese/overweight, however only 9% of Canadian ...
... are high during air travel, and not with other forms of ... blood clots can from during any form of travel where the ... has revealed that traveling for more than four hours by air, ... This was substantiated when the research team analyzed 2000 people, who ...
... phobia or fear of needles can be overcome by ... to researchers at the University of New Mexico's// (UNM) ... needles can impact the care a patient receives. ... of needles, whereas some adults avoid the doctor's office ...
... institutions claim to have found that nearly 19% of ... to a direct// result of war. ,Now ... would get the proper treatment necessary. Their fears see ... now mental health treatment from the Department of Veterans ...
... every month for several problems ranging from arthritis to ... enrolled// in Medicare Part D, the new federal prescription-drug ... plan paid for most of their drugs, minus $20 ... coverage stopped. Donna was told by a pharmacist that ...
Cached Medicine News:Health News:American War Veterans Not Receiving Enough Care For PTSD 2Health News:Many American senior citizens fall into the “Doughnut Hole” 2Health News:Many American senior citizens fall into the “Doughnut Hole” 3Health News:Many American senior citizens fall into the “Doughnut Hole” 4
... remove a cast from an arm or leg ... are cut or burned by the cast saw ... to remove any cast with confidence. This innovative, ... and burns from the cast saw and can ...
... or creation of a vascular access, a ... of the utmost importance in many vascular ... those seeking a high-precision tunneling instrument. The ... of twisting or kinking for more accurate ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
... Stretch Vascular Grafts have met the ... procedures. Recognized for exceptional performance and ... of renowned surgeons worldwide. These grafts ... the spread of infection, and ensure ...
Medicine Products: